首页 | 本学科首页   官方微博 | 高级检索  
     


Evaluation of a Biologic Formulation Using Customized Design of Experiment and Novel Multidimensional Robustness Diagrams
Authors:Radhakrishna K. Maroju  Steve Barash  Charlene E. Brisbane
Affiliation:1. Drug Product Development and Operations, Biologics CMC, Teva Biopharmaceuticals USA, West Chester, Pennsylvania 19380;2. Global Statistics, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, Pennsylvania 19380
Abstract:Formulation development includes selection of appropriate excipients to stabilize the active pharmaceutical ingredient throughout its recommended shelf life, against potential excursions in its life cycle and sometimes to aid in the delivery of therapeutics into the patient. Identity and quantity of every ingredient in a therapeutic formulation are critical to achieve their intended purpose. Deviations from a target composition can result in manufacturing, safety, and efficacy challenges. It is mandatory to establish robustness of a formulation for the expected changes in its composition arising from the qualified “process variability” of the impacting process steps during manufacture. The approach for carrying out a robustness study evolved through improved understanding of a therapeutic stability and exploration of new tools, including the quality by design elements strongly recommended by regulatory agencies. An approach is presented here to study formulation robustness in multidimensional space using a customized experimental design and novel multidimensional diagrams, which present a unique way of identifying robustness limits. The concept is universally applicable to any multivariate analysis and such diagrams would be useful to comprehend the outcome on all variables at a glance. Interpretation of these diagrams is discussed, some of which are applicable in general to any statistical design of experiment.
Keywords:protein formulation  multivariate analysis  biotechnology  stability  excipients  formulation  quality by design  protein excipient interactions  pharmaceutical sciences  biopharmaceuticals characterization  L-Histidine (PubChem CID: 6274)  L-Histidine hydrochloride monohydrate (PubChem CID: 165377)  Sucrose (PubChem CID: 5988)  Polysorbate 80 (PubChem CID: 5281955)  Distilled Water (PubChem CID: 962)  ANOVA  analysis of variance  API  active pharmaceutical ingredient  CMC  chemistry, manufacturing and controls  CQA  critical quality attribute  HPLC  high performance liquid chromatography  ICH  International Council for Harmonization  cIEF  capillary isoelectric focusing  KDa  kilo daltons  MWCO  molecular weight cutoff  PS-80  polysorbate 80  QbD  quality by design  TFA  trifluoroacetic acid  UFDF  ultrafiltration/diafiltration
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号